Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19

Hailing Liu; Shan Meng; Nan Yang; Jinqiu Chen; Huan Yao; Yang Zhang; Hui Zhang; Bo Lei; Xugeng Wang; Sheping Chen; Ting Wang; Yueli Wang; Jin Wang; Wanggang Zhang

doi:10.2217/imt-2019-0197

Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19

Hailing Liu
, Shan Meng
, Nan Yang
, Jinqiu Chen
, Huan Yao
, Yang Zhang
, Hui Zhang
, Bo Lei
, Xugeng Wang
, Sheping Chen
, Ting Wang
, Yueli Wang
, Jin Wang
, Wanggang Zhang

The Second Affiliated Hospital of Xi'an Jiaotong University
The First Affiliated Hospital of Xi’an Jiaotong University
Tongchuan People's Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials & methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collected. Isolated mononuclear cells were treated with two newly designed CpG oligodeoxynucleotides, CpG sequence 13 and 19, and known CpG oligodeoxynucleotides and analyzed via flow cytometry. Results: CpG Seq 13 and 19 possess strong immune activation and enhance the proliferation, degranulation and cytotoxicity of T cells. They also inhibit AML cell proliferation. When CpG Seq 13/19 are combined with anti-OX40 antibodies, the cytotoxicity of T cells on AML cells are further enhanced. Conclusion: CpG Seq 13 and 19 are strong immune adjuvant candidates for AML treatment.

Original language	English
Pages (from-to)	571-585
Number of pages	15
Journal	Immunotherapy
Volume	13
Issue number	7
DOIs	https://doi.org/10.2217/imt-2019-0197
State	Published - May 2021
Externally published	Yes

Keywords

CpG ODNs
OX40
acute myeloid leukemia
immune adjuvant

Access to Document

10.2217/imt-2019-0197

Cite this

@article{dbcd3351cb964ad29b86d5416649c151,

title = "Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19",

abstract = "Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials \& methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collected. Isolated mononuclear cells were treated with two newly designed CpG oligodeoxynucleotides, CpG sequence 13 and 19, and known CpG oligodeoxynucleotides and analyzed via flow cytometry. Results: CpG Seq 13 and 19 possess strong immune activation and enhance the proliferation, degranulation and cytotoxicity of T cells. They also inhibit AML cell proliferation. When CpG Seq 13/19 are combined with anti-OX40 antibodies, the cytotoxicity of T cells on AML cells are further enhanced. Conclusion: CpG Seq 13 and 19 are strong immune adjuvant candidates for AML treatment.",

keywords = "CpG ODNs, OX40, acute myeloid leukemia, immune adjuvant",

author = "Hailing Liu and Shan Meng and Nan Yang and Jinqiu Chen and Huan Yao and Yang Zhang and Hui Zhang and Bo Lei and Xugeng Wang and Sheping Chen and Ting Wang and Yueli Wang and Jin Wang and Wanggang Zhang",

year = "2021",

month = may,

doi = "10.2217/imt-2019-0197",

language = "英语",

volume = "13",

pages = "571--585",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Identification and functional study of novel oligonucleotides

T2 - CpG Seq 13 and CpG Seq 19

AU - Liu, Hailing

AU - Meng, Shan

AU - Yang, Nan

AU - Chen, Jinqiu

AU - Yao, Huan

AU - Zhang, Yang

AU - Zhang, Hui

AU - Lei, Bo

AU - Wang, Xugeng

AU - Chen, Sheping

AU - Wang, Ting

AU - Wang, Yueli

AU - Wang, Jin

AU - Zhang, Wanggang

PY - 2021/5

Y1 - 2021/5

N2 - Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials & methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collected. Isolated mononuclear cells were treated with two newly designed CpG oligodeoxynucleotides, CpG sequence 13 and 19, and known CpG oligodeoxynucleotides and analyzed via flow cytometry. Results: CpG Seq 13 and 19 possess strong immune activation and enhance the proliferation, degranulation and cytotoxicity of T cells. They also inhibit AML cell proliferation. When CpG Seq 13/19 are combined with anti-OX40 antibodies, the cytotoxicity of T cells on AML cells are further enhanced. Conclusion: CpG Seq 13 and 19 are strong immune adjuvant candidates for AML treatment.

AB - Aim: This study explored new immunoadjuvants with stronger immune activity to enhance therapeutic effects against leukemia. Materials & methods: Whole blood and bone marrow of acute myeloid leukemia (AML) patients and healthy volunteers were collected. Isolated mononuclear cells were treated with two newly designed CpG oligodeoxynucleotides, CpG sequence 13 and 19, and known CpG oligodeoxynucleotides and analyzed via flow cytometry. Results: CpG Seq 13 and 19 possess strong immune activation and enhance the proliferation, degranulation and cytotoxicity of T cells. They also inhibit AML cell proliferation. When CpG Seq 13/19 are combined with anti-OX40 antibodies, the cytotoxicity of T cells on AML cells are further enhanced. Conclusion: CpG Seq 13 and 19 are strong immune adjuvant candidates for AML treatment.

KW - CpG ODNs

KW - OX40

KW - acute myeloid leukemia

KW - immune adjuvant

UR - https://www.scopus.com/pages/publications/85104835076

U2 - 10.2217/imt-2019-0197

DO - 10.2217/imt-2019-0197

M3 - 文章

C2 - 33781095

AN - SCOPUS:85104835076

SN - 1750-743X

VL - 13

SP - 571

EP - 585

JO - Immunotherapy

JF - Immunotherapy

IS - 7

ER -

Identification and functional study of novel oligonucleotides: CpG Seq 13 and CpG Seq 19

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this